Attendee search 

Aposave is the global pharmaceutical and healthcare services division of the Abacus Medicine Group.

The company mission is to assist patients with unmet medical needs get access to innovative new medicines, while assisting the manufacturers to maximise the clinical and commercial potential of their assets.

Our promise to healthcare and pharmaceutical customers is to provide a new generation of healthcare and pharmaceutical services to support their new generation of pharmaceutical products throughout the 2020’s and beyond.

To do this Aposave has developed a market leading range of services focused on providing access to medicines around the world. Working across the lifecycle in partnership with pharmaceutical and biotechnology companies Aposave creates and delivers innovative solutions that ensure patients can get timely access to the medicines they need, whilst helping pharmaceutical and biotechnology companies achieve their clinical and commercial objectives.
Aposave has a range of services to support the efficient running of clinical trials called Clinical Trial Solutions (CTS). This is an area where there are great synergies with our parent company, Abacus Medicine. The Abacus Medicine Group holds over 4500 marketing authorisations, and this provides Aposave with unrivalled access to the medicines required to support the running of clinical trials. In addition, Aposave has developed some unique approaches to minimising wastage of products that have expired or are no longer required for a trial.
Aposave has extensive knowledge and experience in managing the distribution of specialty medicines, and this service line is called Specialty Commercial Distribution (SCD). Higher value, lower volume specialty medicines often do not sit well with the traditional distribution model, and this is where our team of experts develop innovative solutions to help ensure patients have access, while maintaining the commercial requirements of our clients.
Aposave is a strategic partner to the pharmaceutical and biotech industry. Aposave Access Programs (AAP) provide a framework for a partnership where Aposave creates, implements, and manages a program on behalf of a drug manufacturer to provide access to their drug in countries where it is not commercially available. This can be either in the prelaunch, or the post launch stage of the product lifecycle. Each program is designed to meet the specific needs of the manufacturer.
The final service that Aposave provides is very much focussed on the patient, and as such is called Individual Access Requests (IAR). Patients with an unmet medical need often require access to a medicine that is not commercially available in the country where they live. When the customer service team at Aposave receive such a request from a healthcare professional, if we do not already have the product in stock, we find a source of the product and ensure we deliver it, in compliance with appropriate regulations, to the relevant medical establishment ready for the patient to receive treatment.

Connexin Therapeutics Ltd. is a UK-based biopharmaceutical company specializing in the discovery and development of drugs targeting connexins, initially for the prevention of vision loss and blindness associated with the eye disease known as glaucoma. While there are a variety of glaucoma subtypes, a common hallmark is the progressive loss of vision due to the gradual cell death in the retina and optic nerve triggered by elevated intraocular pressure. Many drugs are available to reduce intraocular pressure, yet none have been shown to directly protect cells in the retina or optic nerve, and hence prevent them from dying. Thus, vision loss inevitably occurs, even in well-treated patients, and severe vision impairment remains common in these patients.
For 20+ years, our scientific co-founder, Dr. Stewart Bloomfield, has researched and published extensively on the connexin-mediated mechanisms by which elevated intraocular pressure causes cell death in the retina and optic nerve, resulting in vision loss. His research has demonstrated three key points:

1. Retinal and optic nerve cell death is mediated by the bystander effect, which, in turn, mediated by a protein called connexin 36; and

2. Inhibition of connexin 36 prevents further loss of vision in glaucoma; and

3. This inhibition can be achieved using a small molecule drug.

Thus, our goal at Connexin Therapeutics is to develop and partner novel compounds which block connexin 36, thereby preserving vision and potentially preventing blindness in patients with glaucoma. Importantly, glaucoma patients with either elevated or normal intraocular pressure will benefit from retinal neuro-protectants, even in the presence of aggressive attempts to reduce intraocular pressure via drugs or surgery. Other ophthalmic diseases which may benefit from connexin inhibition include subtypes of glaucoma (i.e., normotensive glaucoma), retinitis pigmentosa, and the prevention of corneal scarring secondary to eye surgery. These are indications which may be pursued as the company grows.
In addition to our work with connexin 36 in glaucoma, we may have an opportunity to discover and develop a novel connexin 45 inhibitor. Preliminary work from our laboratory suggests that inhibiting connexin 45 has protective benefits in a range of ischemic ophthalmic conditions, such as diabetic retinopathy. Thus, we have the opportunity to advance two programs from the current round of financing into full development or even licensing.
Interest from multinational pharmaceutical companies in novel compounds to treat ophthalmic conditions is extraordinarily high, as these companies recognize that the rapidly aging population, coupled with significant unmet needs and favorable reimbursement policies, all make for attractive licensing opportunities for companies like Connexin Therapeutics. Thus, we anticipate initiating licensing discussions with pharmaceutical companies as novel connexin inhibitors emerge from our efforts.
Connexin Therapeutics raised ~£150,000 in Seed financing in early 2019. These funds are being used to synthesize and test novel small molecules in animal models of glaucoma. These compounds are based on a molecule which has already demonstrated efficacy in mouse models of glaucoma. Thus, these data supplement and extend the work already published.
We are currently raising ~£2,000,000 to optimize our lead compounds. After ~8-10 quarters of work we anticipate having a library of patentable compounds which are highly selective for connexin 36, backed by primate data. We will have a second compound which inhibits connexin 45 for diabetic retinopathy. Future financing rounds will take one or both leads into clinical trials, while also fueling our expansion into other indications with this same mechanism of action.

ResoTher Pharma is a privately held biotechnology company located in Copenhagen, Denmark. The company is focused on developing peptide-based drugs derived from the endogenous immunomodulator Annexin A1 as resolution therapy for diseases where neutrophil-driven inflammation plays a key pathological role. Our current focus is on cardiovascular disorders and inflammatory disorders with a large unmet medical need. Our lead asset is ready for clinical development in 2021 and expect to reach PoC in myocardial infarction within 3 years.

NxR Biotechnologies is a boutique global consulting firm assisting life science companies and academic institutions conduct business development or investment initiatives. Particularly, NxR provides services for performing strategic, scientific, and commercial assessments; writing business plans; gathering competitive intelligence; and implementing entrepreneurship projects, partnership and in/out-licensing of conventional or regenerative medicine products, and commercialization deals. Areas of focus encompass the pharmaceutical industry and the white biotechnology industry. In the pharmaceutical industry, NxR focuses on cell-based and gene-based therapeutics, nucleic acid therapeutics, and biologics, in oncology, neurodegenerative diseases, inflammation, and rare diseases. In the white biotechnology industry, areas of specialization comprise sustainable chemicals including biomass conversion, biofuels, and polymers, as well as high value-added fermentation products including amino acids, proteins, and pharmaceuticals. NxR's track record comprises projects with big pharmas, biotechs, generics companies, financial investors, CROs, academia, and start-ups.

Founded in 1908, LEO Pharma is an independent, research-based pharmaceutical company, wholly owned by The LEO Foundation and is headquartered in Ballerup, Denmark. LEO Pharma is a leader in medical dermatology and developes, manufactures and markets pharmaceutical drugs for medical dermatology and thrombosis in more than 100 countries globally. We offer patients and physicians highly innovative and well-established products in Psoriasis, Atopic Dermatitis, Eczema, Acne, Rosacea.
LEO Pharma is continuously striving to advance innovation to bring best-in-class and first-in-class medicines in medical dermatology and rare dermatological diseases to create a solid pipeline of assets. LEO Pharma’s mission is to provide people with healthy skin and is has a global dermatology reach employing approximately 6,000 employees worldwide. We serve approximately 92 million patients in 2019 with ambition to serve 125 million patients by 2025.
To realize our vision of becoming the preferred dermatology care partner improving people’s lives around the world, we are constantly looking to collaborate with other companies, Universities to offer patients with therapies that address unmet medical needs in dermatology.

We are keen for In-Licensing Assets for Global and Regional Rights for following: (1) Chinese Rights: innovative (first-in-class or best-in-class) late stage assets (Phase 3 or launched in US, EU or Japan) in medical dermatology or rare dermatological diseases (2) Global Rights: innovative (first-in-class or best-in-class) assets (Pre-clinical through phase III) in medical dermatology or rare dermatological diseases from Asian Biotech companies, Research, and/or academic institutes/universities. (3) VC companies: Who have in their portfolio, companies that have medical dermatology products in their pipeline for China or Global markets (4) Keen to Science and Tech parks in China: Who have companies conducting cutting edge research in medical dermatology
In addition we LEO Pharma has two early stage assets available for partnering.

LEO 142397 (LP0184) is an oral, super selective JAK 1 inhibitor for inflammatory diseases. Product is ready for phase 1 studies. Compound is available for global licensing or acquisition.

LEO 134310 (LP0155) is a SEGRA compound. It is topical, supersoft, non-steroidal Glucocorticoid Receptor (GR) agonist with improved systemic and local safety profile. LP0155 has demonstrated efficacy in clinical phase 1 studies. Compound is available for global licensing or acquisition.

ExoProTher Medical is an Israeli pre-clinical stage company developing a novel biotherapy for cancer treatment, relevant to all cancers with p53 mutation or inactivation - more than 60% of human cancers. Our technology is unique and disruptive and is fully owned by the company.

The company has been funded by private investors. We are currently working on shaping our next funding round.